Athenex Inc (ATNX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Athenex Inc (NASDAQ:ATNX) have been given an average recommendation of “Buy” by the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.64.

Several equities analysts have recently weighed in on ATNX shares. JPMorgan Chase & Co. started coverage on Athenex in a research note on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price objective on the stock. Credit Suisse Group started coverage on Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price objective on the stock. Royal Bank of Canada started coverage on Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price objective on the stock. Laidlaw started coverage on Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a research note on Thursday.

Athenex (ATNX) opened at $15.94 on Thursday. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System acquired a new position in shares of Athenex in the 3rd quarter valued at about $198,000. Bank of New York Mellon Corp acquired a new position in Athenex during the 2nd quarter worth approximately $240,000. Tudor Investment Corp ET AL acquired a new position in Athenex during the 2nd quarter worth approximately $320,000. Schwab Charles Investment Management Inc. acquired a new position in Athenex during the 3rd quarter worth approximately $524,000. Finally, Goldman Sachs Group Inc. acquired a new position in Athenex during the 2nd quarter worth approximately $601,000. 2.93% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Athenex Inc (ATNX) Given Consensus Recommendation of “Buy” by Brokerages” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2018/01/04/athenex-inc-atnx-given-consensus-recommendation-of-buy-by-brokerages.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit